Evidence map›Paper›PMID 31061837›Full record

ArticleMovement disorders clinical practice2019

The Parkinson's Disease Sleep Scale-2 (PDSS-2): Validation of the Spanish Version and Its Relationship With a Roommate-Based Version.

Pablo Martinez-Martin, John B Wetmore, Carmen Rodríguez-Blázquez, Tomoko Arakaki, Oscar Bernal, Victor Campos-Arillo, Christopher Cerda, Ingrid Estrada-Bellmann, Nélida Garretto, Letty Ginsburg and 7 more

Abstract read
In one paragraph

Article in Movement disorders clinical practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Pablo Martinez-MartinNational Center of Epidemiology Carlos III Institute of Health Madrid Spain.ORCID https://orcid.org/0000-0003-0837-5280
John B WetmoreNational Center of Epidemiology Carlos III Institute of Health Madrid Spain.
Carmen Rodríguez-BlázquezNational Center of Epidemiology Carlos III Institute of Health Madrid Spain.
Tomoko ArakakiParkinson Disease and Other Movement Disorders Unit Hospital José María Ramos Mejía, Neurology University Center of Buenos Aires University Buenos Aires Argentina.
Oscar BernalMovement Disorders Clinic Hospital Militar Central Bogotá Colombia.
Victor Campos-ArilloÁrea de Neurociencias Hospitales Vithas-Málaga Málaga Spain.
Christopher CerdaMovement Disorder Clinic University Hospital Monterrey Nuevo León México.
Ingrid Estrada-BellmannMovement Disorder Clinic University Hospital Monterrey Nuevo León México.
Nélida GarrettoParkinson Disease and Other Movement Disorders Unit Hospital José María Ramos Mejía, Neurology University Center of Buenos Aires University Buenos Aires Argentina.
Letty GinsburgMovement Disorders Division Miller School of Medicine, University of Miami Miami Florida USA.
Jorge Uriel Máñez-MiróMovement Disorders Unit, Neurology department La Paz University Hospital Madrid Spain.ORCID https://orcid.org/0000-0002-8995-8340
Juan Carlos Martínez-CastrilloMovement Disorders and Neurodegenerative Disorders Unit IRYCIS, Hospital Ramon y Cajal Madrid Spain.
Ivonne PedrosoMovement Disorders Clinic International Center for Neurological Restoration (CIREN) Havana Cuba.
Marcos Serrano-DueñasMedicine Faculty, Pontifical Catholic University of Ecuador Movement Disorders Unit, Neurological Service, Carlos Andrade Marín Hospital Quito Ecuador.
Carlos SingerMovement Disorders Division Miller School of Medicine, University of Miami Miami Florida USA.
Mayela Rodríguez-ViolanteMovement Disorders Clinic National Institute of Neurology and Neurosurgery Mexico City Mexico.ORCID https://orcid.org/0000-0002-6041-9941
Francisco VivancosMovement Disorders Unit, Neurology department La Paz University Hospital Madrid Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBecause of the prevalence and impact of sleep disorders in Parkinson's disease (PD), valid instruments for their evaluation and monitoring are necessary. However, some nocturnal sleep disorders may go unnoticed by patients themselves.

objectivesTo validate a pan-Spanish version of the Parkinson's Disease Sleep Scale Version 2 (PDSS-2) and to test the relationships between the PDSS-2 and a PDSS-2 roommate version.

methodsPD patients (n = 399) from seven Spanish-speaking countries were included. In addition to the tested PDSS-2 scales, valid measures for sleep disorders and both motor and nonmotor manifestations were applied. Acceptability, dimensionality, reliability, precision, and construct validity were explored, as well as discrepancies and agreement between the PDSS-2 and the roommate version.

resultsPDSS-2 showed negligible floor and ceiling effects. Four factors (57% of the variance) were identified. Reliability parameters were satisfactory: alpha = 0.84; item homogeneity coefficient = 0.27; corrected item total correlation = 0.28 to 0.61; and test-retest reliability (average kappa = 0.70; intraclass correlation coefficient [ICC] = 0.83). The standard error of measurement was 5.84, and correlations with other scales assessing nocturnal sleep were high (r

conclusionsThe Spanish version of the PDSS-2 has shown satisfactory clinimetric attributes. Acceptability and precision data are presented for the first time. The PDSS-2 roommate version could be useful to complement the patient-based evaluation, but additional studies are needed.

Indexed as

clinimetric propertiesParkinson's diseasePDSS‐2PDSS‐2 Roommate versionSpanish version

Identifiers

PMID31061837
PMCPMC6476589

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.